Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) shares fell sharply during Friday’s session after the company released topline results of the ARISE-HF Phase 3 trial of AT-001 (caficrestat) in patients with Diabetic Cardiomyopathy (DbCM) at high risk of progression to overt heart failure.
The study's primary endpoint was stabilization or improvement in cardiac functional capacity as measured by Peak VO2 in patients treated with AT-001 1500mg twice daily (BID) compared to placebo.
Applied Therapeutics shares dipped 35.6% to $2.4498 on Friday.
Here are some other stocks moving in today's mid-day session.
Gainers
Losers
Now Read This: Insiders Buying Synchronoss Technologies And 2 Other Stocks
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
